- Revenue Growth: ACADIA recorded Q4 adjusted total revenues of $298M (+16% YoY) and $1.08B for 2025 (+14% YoY).
- Product Performance: NUPLAZID net sales hit $189M in Q4 (+17% YoY) and $692M annually (+15% YoY), while DAYBUE reached $110M in Q4 (+13% YoY) and $391M annually (+12% YoY).
- R&D Pipeline: 4 molecules target $11B peak sales, with 5 Phase II/III studies planned by 2027. Phase II remlifanserin results expected August–October 2026.
- 2026 Guidance: Total revenue projected at $1.22B–$1.28B. NUPLAZID: $760M–$790M (10–14% growth); DAYBUE: $460M–$490M (18–25% growth).
- Financial Strength: $820M cash balance and $250M noncash tax benefit. Operating margins expected to reach mid-teens by 2028, with CAGR of ~16% over the growth period.
Revenue Growth Drivers
The strong commercial performance of NUPLAZID, with 18% year-over-year growth in new prescriptions in Q4, was a key driver of revenue growth. DAYBUE sales also grew 13% year-over-year in Q4, driven by strong U.S. performance and growing contributions from rest-of-world programs. As Mark Schneyer, Chief Financial Officer, noted, the company's revenue growth is expected to continue, with NUPLAZID net sales expected to reach $760 million to $790 million in 2026, representing 10% to 14% growth over 2025 adjusted net sales.
Valuation Metrics
To understand what's priced into ACADIA Pharmaceuticals' stock, we can look at various valuation metrics. The company's P/E Ratio is 10.64, indicating a relatively reasonable valuation compared to its earnings. The P/S Ratio is 3.88, suggesting that the stock may be slightly overvalued relative to its sales. Additionally, the EV/EBITDA ratio is 25.69, which may indicate a high valuation relative to its earnings before interest, taxes, depreciation, and amortization.
Pipeline and Future Prospects
The company's robust R&D pipeline, with 4 unique molecules targeting large addressable markets with combined peak sales potential of $11 billion, is expected to drive future growth. The company expects to initiate 5 additional Phase II or Phase III studies by the end of 2027. Top-line results from the Phase II study of remlifanserin in Alzheimer's disease psychosis are expected between August and October 2026, which could be a significant catalyst for the stock.
Guidance and Expectations
For fiscal year 2026, the company expects total revenues to be between $1.22 billion and $1.28 billion, representing year-over-year growth. NUPLAZID is expected to have net sales between $760 million and $790 million, driven by expanding volume, while DAYBUE is expected to have net sales between $460 million and $490 million, driven by DAYBUE STIX and growth in named patient supply programs. Analysts estimate next year's revenue growth at 11.5%, which is slightly lower than the company's expected growth rate.